
Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 0.30 | 6.26 | 5.96 |
Shares | 97.48 | 97.48 | 0.00 |
Bonds | 0.01 | 0.01 | 0.00 |
Preferred | 0.11 | 0.11 | 0.00 |
Other | 2.09 | 2.19 | 0.10 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 11.81 | 13.47 |
Price to Book | 1.65 | 1.92 |
Price to Sales | 1.18 | 1.28 |
Price to Cash Flow | 8.05 | 8.83 |
Dividend Yield | 3.87 | 3.54 |
5 Years Earnings Growth | 9.09 | 9.17 |
Name | Net % | Category Average |
---|---|---|
Financial Services | 22.15 | 20.34 |
Industrials | 15.18 | 15.30 |
Healthcare | 13.80 | 11.32 |
Consumer Defensive | 13.76 | 14.27 |
Energy | 12.00 | 10.17 |
Consumer Cyclical | 7.32 | 9.76 |
Basic Materials | 5.37 | 6.98 |
Utilities | 4.59 | 3.66 |
Communication Services | 3.61 | 5.68 |
Real Estate | 1.33 | 2.49 |
Technology | 0.90 | 3.12 |
Number of long holdings: 105
Number of short holdings: 4
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
AstraZeneca | GB0009895292 | 8.20 | 10,400.0 | -0.42% | |
Shell | GB00BP6MXD84 | 8.05 | 28.97 | +1.08% | |
HSBC | GB0005405286 | 7.47 | 834.00 | +0.81% | |
Unilever | GB00B10RZP78 | 5.86 | 54.94 | -2.14% | |
Relx | GB00B2B0DG97 | 3.55 | 4,003.00 | +0.91% | |
BP | GB0007980591 | 3.32 | 364.45 | +0.62% | |
London Stock Exchange | GB00B0SWJX34 | 2.95 | 11,440.0 | -0.39% | |
Diageo | GB0002374006 | 2.95 | 2,065.0 | -1.48% | |
GSK plc | GB00BN7SWP63 | 2.82 | 1,389.00 | -0.36% | |
Rio Tinto PLC | GB0007188757 | 2.64 | 4,550.0 | -1.37% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Halifax International Growth Fund A | 3.32B | -3.58 | 7.70 | 10.20 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review